Novo Nordisk Accused Of Fixing Prices To Hide Sales Slump
A Pennsylvania retirement fund accused Novo Nordisk A/S of hiding increasingly poor financial results from investors in part by colluding with its competitors to raise prices, according to a proposed class...To view the full article, register now.
Already a subscriber? Click here to view full article